Multi‐Omics Approach Points to the Importance of Oxylipins Metabolism in Early‐Stage Breast Cancer

The involvement of oxylipins, metabolites of polyunsaturated fatty acids, in cancer path-ogenesis was known long ago, but only the development of the high‐throughput methods get the opportunity to study oxylipins on a system level. The study aimed to elucidate alterations in ox-ylipin metabolism as characteristics of breast cancer patients. We compared the ultra‐high‐perfor-mance liquid chromatography‐mass spectrometry (UPLC‐MS/MS) oxylipin profile signatures in the blood plasma of 152 healthy volunteers (HC) and 169 patients with different stages of breast cancer (BC). To integrate lipidomics, transcriptomics, and genomics data, we analyzed a transcriptome of 10 open database datasets obtained from tissues and blood cells of BC patients and SNP data for 33 genes related to oxylipin metabolism. We identified 18 oxylipins, metabolites of omega‐3 or omega‐ 6 polyunsaturated fatty acids, that were differentially expressed between BCvsHC patients, includ-ing anandamide, prostaglandins and hydroxydocosahexaenoic acids. DEGs analysis of tissue and blood samples from BC patients revealed that 19 genes for oxylipin biosynthesis change their expression level, with CYP2C19, PTGS2, HPGD, and FAAH included in the list of DEGs in the analysis of transcriptomes and the list of SNPs associated with BC. Results allow us to suppose that oxylipin signatures reflect the organism’s level of response to the disease. Our data regarding changes in oxylipins at the system level show that oxylipin profiles can be used to evaluate the early stages of breast cancer. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.